News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,104 Results
Type
Article (14730)
Company Profile (67)
Press Release (268304)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (101458)
Career Advice (468)
Deals (15518)
Drug Delivery (102)
Drug Development (36998)
Employer Resources (51)
FDA (6471)
Job Trends (6284)
News (151429)
Policy (14197)
Tag
2025 Best Places to Work (7)
2026 Best Places to Work (13)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
40 Under 40 (2)
Academia (470)
Accelerated approval (33)
ADA (11)
Adcomms (9)
Allergies (117)
Alliances (23381)
ALS (87)
Alzheimer's disease (588)
Antibody-drug conjugate (ADC) (239)
Approvals (6932)
Artificial intelligence (357)
ASCO (114)
Autoimmune disease (118)
Automation (26)
Bankruptcy (155)
Belgium (6)
Best Places to Work (4385)
BIO (26)
Biologics (49)
BIOSECURE Act (9)
Biosimilars (199)
BioSpace Insights (72)
Biotechnology (30)
Bispecific (13)
Bladder cancer (61)
Brain cancer (45)
Breast cancer (254)
Cancer (2098)
Cardiovascular disease (250)
Career advice (430)
Career pathing (15)
CAR-T (81)
CDC (11)
CDMO (101)
Celiac Disease (1)
Cell therapy (234)
Cervical cancer (25)
Clinical research (33354)
Collaboration (1146)
Commercialization (37)
Company closure (3)
Compensation (483)
Complete response letters (54)
COVID-19 (799)
CRISPR (68)
CRO (4)
C-suite (859)
Cystic fibrosis (68)
Data (3289)
Decentralized trials (2)
Denatured (19)
Depression (68)
Dermatology (41)
Diabetes (200)
Diagnostics (1537)
Digital health (19)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (215)
Drug pricing (126)
Drug shortages (16)
Duchenne muscular dystrophy (119)
Earnings (35058)
Editorial (25)
Employer branding (4)
Employer resources (47)
ESMO (122)
Events (40810)
Executive appointments (707)
Eye disease (4)
FDA (8245)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (4)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (668)
Gene editing (104)
Generative AI (38)
Gene therapy (240)
GLP-1 (533)
Government (1457)
Grass and pollen (4)
Guidances (178)
Healthcare (3702)
Hematology (77)
HIV (23)
Huntington's disease (16)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (72)
Immunology and inflammation (103)
Immuno-oncology (46)
Indications (139)
Infectious disease (919)
Inflammatory bowel disease (98)
Inflation Reduction Act (7)
Influenza (31)
Intellectual property (169)
Interviews (59)
IPO (5959)
IRA (33)
Job creations (2062)
Job search strategy (378)
JPM (29)
Kidney cancer (19)
Kidney disease (61)
Labor market (50)
Layoffs (226)
Leadership (14)
Legal (3458)
Licensing (81)
Liver cancer (27)
Longevity (18)
Lung cancer (299)
Lung diease (5)
Lymphoma (187)
Machine learning (17)
Management (18)
Manufacturing (768)
Marketing (21)
MASH (106)
Medical affairs (3)
Medical device (1331)
Medtech (1358)
Melanoma (58)
Mergers & acquisitions (10207)
Metabolic disorders (670)
Middle East (1)
mRNA (81)
Multiple sclerosis (74)
Multispecific (1)
NASH (15)
Netherlands (7)
Neurodegenerative disease (145)
Neuropsychiatric disorders (57)
Neuroscience (1254)
Neurotech (2)
NextGen: Class of 2026 (1588)
Non-profit (615)
Now hiring (31)
Obesity (344)
Opinion (158)
Ovarian cancer (83)
Pain (168)
Pancreatic cancer (86)
Parkinson's disease (130)
Partnered (15)
Patents (348)
Patient advocacy (1)
Patient recruitment (237)
Patient selection (33)
Peanut (18)
People (30799)
Peptides (19)
Pharmaceutical (34)
Pharmacy benefit managers (20)
Phase 1 (8605)
Phase 2 (14063)
Phase 3 (12778)
Pipeline (5237)
Policy (167)
Postmarket research (1407)
Preclinical (3467)
Press Release (25)
Prostate cancer (135)
Psychedelics (32)
Radioligand (1)
Radiopharmaceuticals (193)
Rare diseases (610)
Real estate (2674)
Recruiting (19)
Regenerative medicine (7)
Regulatory (11977)
Reports (24)
Research institute (589)
Resumes & cover letters (55)
Rett syndrome (18)
RNA editing (10)
RSV (29)
Saudi Arabia (1)
Schizophrenia (105)
Series A (134)
Series B (75)
Series C (1)
Service/supplier (1)
Sickle cell disease (68)
Special edition (15)
Spinal muscular atrophy (86)
Sponsored (13)
Startups (1664)
State (2)
Stem cells (2)
Stomach cancer (8)
Substance use disorders (7)
Supply chain (78)
Switzerland (13)
Tariffs (72)
The Weekly (57)
Vaccines (316)
Venture capital (57)
Weight loss (193)
Wet AMD (4)
Women's health (69)
Worklife (5)
Date
Today (51)
Last 7 days (279)
Last 30 days (1241)
Last 365 days (10726)
2026 (9823)
2025 (10752)
2024 (12506)
2023 (14282)
2022 (19595)
2021 (20092)
2020 (19044)
2019 (14886)
2018 (11715)
2017 (13899)
2016 (13131)
2015 (15488)
2014 (12443)
2013 (10610)
2012 (11414)
2011 (11965)
2010 (10933)
Location
Africa (328)
Alabama (25)
Alaska (1)
Arizona (111)
Arkansas (4)
Asia (21683)
Australia (2790)
California (4735)
Canada (2138)
China (959)
Colorado (210)
Connecticut (208)
Delaware (206)
Europe (42879)
Florida (897)
Georgia (90)
Hawaii (2)
Idaho (11)
Illinois (548)
India (105)
Indiana (381)
Iowa (3)
Japan (459)
Kansas (93)
Kentucky (23)
Louisiana (8)
Maine (2)
Maryland (584)
Massachusetts (3816)
Michigan (59)
Minnesota (245)
Mississippi (2)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (26)
New Hampshire (9)
New Jersey (2131)
New Mexico (7)
New York (1359)
North Carolina (872)
North Dakota (2)
Northern California (2296)
Ohio (117)
Oklahoma (6)
Oregon (17)
Pennsylvania (1018)
Puerto Rico (23)
Rhode Island (19)
South America (510)
South Carolina (16)
Southern California (2106)
Tennessee (84)
Texas (663)
United States (18704)
Utah (78)
Vermont (1)
Virginia (252)
Washington D.C. (42)
Washington State (349)
West Virginia (1)
Wisconsin (78)
Wyoming (2)
283,104 Results for "galmed pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
April 4, 2024
·
5 min read
Business
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments
June 1, 2023
·
8 min read
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
Galmed Pharmaceuticals Ltd. reported the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M.
May 4, 2023
·
7 min read
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”) announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.
March 15, 2024
·
6 min read
Deals
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Galmed Pharmaceuticals Ltd. announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the “Offering”).
July 14, 2023
·
6 min read
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
November 20, 2023
·
5 min read
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - September 22, 2023
Galmed Pharmaceuticals Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.
September 22, 2023
·
5 min read
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.
September 26, 2023
·
6 min read
Business
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.
May 17, 2022
·
8 min read
Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission.
March 29, 2023
·
4 min read
1 of 28,311
Next